{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007826","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.557356+00:00","generated_at":"2026-06-25T23:45:25.180207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Q1 revenue $29M (+55% YoY), net loss ($9.0M), raises FY guidance to $128-133M","bullets":["Revenue of $29.0M, up 55% from $18.7M in Q1 2021; driven by increased Lapiplasty kit sales and higher ASPs.","Net loss attributable to common stockholders was ($9.0M), or ($0.16) per share, vs. ($2.6M) or ($0.07) in Q1 2021.","Gross margin 81.0% (down from 82.2%); operating expenses rose to $31.6M from $16.8M on higher S&M and G&A investments.","New five-year $150M loan arrangement ($120M term loan + $30M revolver); $54M drawn to repay existing $30M debt.","FY 2022 revenue guidance raised to $128M-$133M (prior $125M-$130M); representing ~36%-41% YoY growth."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007826","json":"https://secwatch.observer/filing/0000950170-22-007826.json","markdown":"https://secwatch.observer/filing/0000950170-22-007826.md","text":"https://secwatch.observer/filing/0000950170-22-007826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/0000950170-22-007826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/tmci-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:45:25.180207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}